Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Potential risks and prevention, Part 3: Drug-induced threats to life.

Marcellino K, Kelly WN.

Am J Health Syst Pharm. 2001 Aug 1;58(15):1399-405. Review.

PMID:
11494784
2.

Potential risks and prevention, Part 4: Reports of significant adverse drug events.

Kelly WN.

Am J Health Syst Pharm. 2001 Aug 1;58(15):1406-12. Review.

PMID:
11494785
3.

Potential risks and prevention, Part 2: Drug-induced permanent disabilities.

Kelly WN.

Am J Health Syst Pharm. 2001 Jul 15;58(14):1325-9. Review.

PMID:
11471480
4.

Potential risks and prevention, Part 1: Fatal adverse drug events.

Kelly WN.

Am J Health Syst Pharm. 2001 Jul 15;58(14):1317-24. Review.

PMID:
11471479
5.

The epidemiology of preventable adverse drug events: a review of the literature.

von Laue NC, Schwappach DL, Koeck CM.

Wien Klin Wochenschr. 2003 Jul 15;115(12):407-15. Review.

PMID:
12918183
6.

Nature of preventable adverse drug events in hospitals: a literature review.

Kanjanarat P, Winterstein AG, Johns TE, Hatton RC, Gonzalez-Rothi R, Segal R.

Am J Health Syst Pharm. 2003 Sep 1;60(17):1750-9. Review.

PMID:
14503111
7.

Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care.

Thomsen LA, Winterstein AG, Søndergaard B, Haugbølle LS, Melander A.

Ann Pharmacother. 2007 Sep;41(9):1411-26. Epub 2007 Jul 31. Review.

PMID:
17666582
8.

The quality of published adverse drug event reports.

Kelly WN.

Ann Pharmacother. 2003 Dec;37(12):1774-8. Review.

PMID:
14632590
9.

Drug-associated anaphylaxis: 20 years of reporting in The Netherlands (1974-1994) and review of the literature.

van der Klauw MM, Wilson JH, Stricker BH.

Clin Exp Allergy. 1996 Dec;26(12):1355-63. Review.

PMID:
9027435
10.

Patient reporting of suspected adverse drug reactions: a review of published literature and international experience.

Blenkinsopp A, Wilkie P, Wang M, Routledge PA.

Br J Clin Pharmacol. 2007 Feb;63(2):148-56. Review.

11.

Adverse drug events in the elderly.

Cresswell KM, Fernando B, McKinstry B, Sheikh A.

Br Med Bull. 2007;83:259-74. Epub 2007 Jun 18. Review.

PMID:
17580312
12.

Medical errors challenges for the health professionals: need of Pharmacovigilance to prevent.

Das BP, Rauniar GP, Bhattacharya SK.

JNMA J Nepal Med Assoc. 2006 Apr-Jun;45(162):273-8. Review.

PMID:
18365356
13.

Drug-induced myoclonus: a French pharmacovigilance database study.

Brefel-Courbon C, Gardette V, Ory F, Montastruc JL.

Neurophysiol Clin. 2006 Sep-Dec;36(5-6):333-6. Epub 2007 Jan 25. Review.

PMID:
17336778
14.

Preventing adverse drug events in hospital practice: an overview.

Rommers MK, Teepe-Twiss IM, Guchelaar HJ.

Pharmacoepidemiol Drug Saf. 2007 Oct;16(10):1129-35. Review.

PMID:
17610221
15.

An analysis of Australian adverse drug events.

Malpass A, Helps SC, Runciman WB.

J Qual Clin Pract. 1999 Mar;19(1):27-30. Review.

PMID:
10096721
16.

Physicians' liability for adverse drug reactions.

Kaufman MB, Stoukides CA, Campbell NA.

South Med J. 1994 Aug;87(8):780-4. Review.

PMID:
8052883
17.

Identifying high-risk medication: a systematic literature review.

Saedder EA, Brock B, Nielsen LP, Bonnerup DK, Lisby M.

Eur J Clin Pharmacol. 2014 Jun;70(6):637-45. doi: 10.1007/s00228-014-1668-z. Epub 2014 Mar 27. Review.

PMID:
24671697
18.

Adverse drug effects.

Lamy PP.

Clin Geriatr Med. 1990 May;6(2):293-307. Review.

PMID:
2184925
19.

Can the frequency and risks of fatal adverse drug events be determined?

Kelly WN.

Pharmacotherapy. 2001 May;21(5):521-7. Review.

PMID:
11349740
20.

Epidemiology and characteristics of adverse drug reactions caused by drug-drug interactions.

Magro L, Moretti U, Leone R.

Expert Opin Drug Saf. 2012 Jan;11(1):83-94. doi: 10.1517/14740338.2012.631910. Epub 2011 Oct 25. Review.

PMID:
22022824

Supplemental Content

Support Center